Check out this recent study by Dr. Alberto Esquenazi & colleagues that found aboBoNT‑A was non‑inferior in safety & showed slightly longer response duration—about 3 extra days—compared with onaBoNT‑A. These findings offer clearer guidance for spasticity treatment decisions. https://ow.ly/UReF50Z5JrI
